BREAST CANCER

During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.

Laura Huppert, MD, discussed a retrospective study exploring the sequential use of antibody-drug conjugates for the treatment of HER2-low metastatic breast cancer.

During a Case-Based Roundtable® event, Igor Makhlin, MD, discussed with participants their impressions of datopotamab deruxtecan as therapy for patients with HR-positive, HER2-negative breast cancer, and the sequential use of multiple antibody-drug conjugates.

Erika Hamilton, MD, discussed findings from the phase 1b/2 ELECTRA study investigating a new oral combination therapy for patients with metastatic breast cancer.

Laura Huppert, MD, and Aditya Bardia, MD, MPH, FASCO, provide closing thoughts on the evolving treatment landscape for HER-negative and HER2-low metastatic breast cancer.

A phase 1 trial is underway to assess the safety and efficacy of BTX-9341, a novel investigational oral degrader of CDK4/6 in HR-positive/HER2-negative breast cancer.

In a live virtual event, Aditya Bardia, MD, MPH, discussed the treatment landscape for patients with advanced invasive breast cancer.

Denise Yardley, MD, discusses the takeaways and next steps of an analysis of the NATALEE trial investigating ribociclib in node-negative breast cancer.

In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.

Medical oncologists share clinical practices for selecting and sequencing TROP2-directed antibody-drug conjugates, highlighting ideal candidates for sacituzumab govitecan or datopotamab deruxtecan.

Experts on breast cancer offer comprehensive insights on findings from the TROPiCS-02 study investigating sacituzumab govitecan in patients with HR+/HER2- metastatic or locally recurrent inoperable breast cancer.

Breast cancer specialists review the study design, efficacy data, and safety profile findings from the TROPION-Breast01 study investigating datopotamab deruxtecan (Dato-DXd) in patients with HR+/HER2- metastatic breast cancer.

Medical oncologists provide insights on emerging pathways and TROP2-directed antibody-drug conjugates in HR+/HER2- metastatic breast cancer, highlighting ongoing research.

Hope S. Rugo, MD, discusses the ELEVATE trial of elacestrant combined with various targeted therapies for patients with endocrine receptor-positive/HER2-negative metastatic breast cancer who have already received endocrine therapy and CDK4/6 inhibitors.

Tanya Gupta, MD, discusses the current landscape of antibody-drug conjugates for breast cancer subtypes beyond HER2-positive disease.

The FDA approved Tepylute, a ready-to-dilute formulation of an existing treatment for breast and ovarian adenocarcinoma.

Laura Huppert, MD, and Aditya Bardia, MD, MPH, FASCO, share advice for community oncologists on the utilization of T-DXd and discuss the future outlook for antibody-drug conjugates in HR+/HER2-low breast cancer.

Experts on breast cancer describe the best candidates for HER2-directed antibody-drug conjugates in HR+/HER2-low metastatic breast cancer, highlighting the role of trastuzumab deruxtecan in later lines of therapy.

Recent approvals herald novel strategies for addressing advanced or metastatic breast cancer with ESR1 mutations.

Ali Duffens, MD, discusses a study in which investigators assessed the mode of detection for breast cancer recurrence within an integrated health system by assessing the utility and outcomes of current surveillance guidelines recommended by the National Comprehensive Cancer Network.

Tanya Gupta, MD, highlighted the approved indications for antibody-drug conjugates in breast cancer, the efficacy data supporting their approvals, and ongoing studies to advance the space further.

Breast cancer specialists review key efficacy and safety data from the DESTINY-Breast04 trial investigating trastuzumab deruxtecan in patients with HR+/HER2-low metastatic breast cancer.

Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, discuss treatment sequencing practices and ongoing challenges in patients with HR+/HER2-low breast cancer.

During a Case-Based Roundtable® event, Timothy J. Pluard, MD, explores datopotamab deruxtecan as an option in hormone receptor–positive, HER2-negative breast cancer in the second article of a 2-part series.

Capivasertib combined with paclitaxel failed to improve overall survival in a phase 3 trial CAPItello-290 in metastatic triple-negative breast cancer, missing the study’s dual primary end points.